8-K: Neogen Reports FY26 Results, Eyes FY27 Growth

Neogen Corporation announced its fiscal year 2026 fourth quarter and full fiscal year results, highlighting strong core growth in Food Safety and providing financial guidance for fiscal year 2027.

Summary

• Neogen Corporation reported fourth quarter fiscal year 2026 revenue of $225.3 million, a slight decrease of 0.1% year-over-year, but with core growth of 4.3%.
• Full fiscal year 2026 revenue was $870.4 million, down 2.7% from the prior year, with core growth of 1.9%.
• The Food Safety segment showed strong performance with fourth quarter revenue growth of 3.1% and core growth of 5.8%, the highest since FY23.
• The Animal Safety segment revenue declined 8.2% in the fourth quarter, but showed a 0.5% core growth and a 7% sequential increase due to resolved supply challenges.
• The company reported a net loss of $11.3 million for the fourth quarter, with an Adjusted Net Income of $18.7 million and Adjusted EPS of $0.09.
• Fourth quarter cash flow from operations was $30.2 million, and free cash flow was $26.2 million.
• Adjusted EBITDA for the fourth quarter was $45.4 million, with a margin of 20.2%.
• Neogen provided financial guidance for FY2027, projecting revenue between $880-$885 million and Adjusted EBITDA of $180-$182 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with clear signs of operational recovery and core business strength, though overall revenue remains slightly down year-over-year.

Positives

• Fourth quarter core revenue growth of 4.3% was the highest rate in fiscal year 2026.
• Food Safety segment core growth of 5.8% in Q4 FY26 was the highest since FY23.
• Indicator Testing and Culture Media revenue grew 9.5% in Q4 FY26.
• Bacterial and General Sanitation revenue grew 9.9% in Q4 FY26.
• Animal Safety segment revenue increased 7% sequentially in Q4 FY26 due to resolution of supply challenges.
• Gross margin improved to 47.8% in Q4 FY26 from 41.2% in the prior year quarter.
• Adjusted Gross Margin improved to 49.7% in Q4 FY26 from 46.4% in the prior year quarter.
• Adjusted EBITDA margin improved to 20.2% in Q4 FY26 from 18.0% in the prior year quarter.

Negatives

• Total revenue for fiscal year 2026 decreased by 2.7% to $870.4 million.
• Animal Safety segment revenue decreased by 8.2% in the fourth quarter.
• Rodent Control, Insect Control & Disinfectants revenue in Food Safety decreased by 65.5% in Q4 FY26.
• Rodent Control, Insect Control & Disinfectants revenue in Animal Safety decreased by 22.3% in Q4 FY26.
• Net loss for the fourth quarter was $11.3 million.
• The company is still working through regulatory reviews for its genomics business divestiture in Australia and New Zealand.
• The company anticipates a negative impact from currency exchange rates in FY27 guidance.
• The company is not able to reconcile forward-looking Adjusted EBITDA to GAAP net income due to the uncertainty of certain items.

Risks

• Risks related to the continued integration of the 3M Food Safety business.
• Potential tax benefits realized through the 3M transaction.
• Tariffs and other trade measures.
• Risks associated with international operations and expansion into new geographic markets.
• Identified material weaknesses in internal controls over financial reporting.
• Potential failures of systems infrastructure and security breaches.
• Disruption in manufacturing and service operations.
• Dependence on key suppliers and third-party delivery services.

Future Outlook

For fiscal year 2027, Neogen projects total revenue between $880 million and $885 million, and Adjusted EBITDA between $180 million and $182 million. This guidance includes an estimated $92 million in revenue and $13 million in Adjusted EBITDA from the Genomics division, which is planned to be divested. Management intends to update guidance post-divestiture. The company anticipates core growth of approximately 3% for FY27, excluding certain items, and assumes a 1% negative impact from currency. For the first quarter of fiscal year 2027, revenue is projected between $207-$209 million and Adjusted EBITDA around $37 million, with typical seasonality and mix changes impacting Q1 negatively.

Management Comments

• "We ended fiscal year 2026 with significant momentum and have a number of initiatives underway to further enhance our commercial efforts and the way we approach customers and our core markets."
• "Fiscal year 2027 will be a year of disciplined execution and investment in core areas as we look to drive high-impact innovation and operational efficiency through additive technology and improved process."
• "Ultimately, our goal is to exit FY27 positioned for enhanced future growth and profitability."
• "We are providing our fiscal guidance for 2027, and we have stayed true to our principles of delivering on our commitments."
• "Our entire organization is focused on disciplined execution and sustaining the operational momentum that we have seen in the business throughout fiscal year 2026."
• "I'm extremely proud of our team and want to thank our employees for their significant contributions to the success of our company."

Industry Context

StockSavvy.ai notes that Neogen's focus on core growth in its Food Safety segment, particularly in indicator testing and culture media, aligns with increasing global demand for robust foodborne pathogen detection and quality assurance solutions. The company's efforts to resolve supply chain issues in Animal Safety also reflect broader industry challenges in managing production and logistics.

Comparison to Industry Standards

• Neogen's Q4 FY26 Adjusted EBITDA margin of 20.2% is competitive within the specialized diagnostics and safety solutions sector, though specific peer comparisons require detailed analysis of companies with similar product portfolios and market focus.
• The company's core revenue growth of 4.3% in Q4 FY26, while positive, is moderate compared to high-growth segments within the broader life sciences industry, but indicates stabilization and recovery after a period of decline.
• The planned divestiture of the Genomics business to Zoetis Inc. for $160 million is a strategic move to streamline operations and focus on core strengths, a trend seen across various companies seeking to optimize their business units for better performance and valuation.

Legal Proceedings

• The company is cooperating with the Australian Competition and Consumer Commission (ACCC) and the New Zealand Commerce Commission (NZCC) as they conduct second-phase reviews of the proposed genomics divestiture.

Stakeholder Impact

• Shareholders: Potential for improved profitability and growth in FY27, contingent on successful execution of strategic initiatives and the genomics divestiture.
• Employees: Continued focus on disciplined execution and operational efficiency may lead to a more stable and growth-oriented work environment.
• Customers: Improved product availability (Animal Safety) and continued innovation (Food Safety) are expected.
• Suppliers: Resolution of supply chain issues in Animal Safety may lead to more predictable demand.
• Creditors: The planned use of proceeds from the genomics divestiture for debt reduction is positive for leverage ratios.

Next Steps

• Complete the sale of the global Genomics business to Zoetis Inc. by the end of the first half of fiscal year 2027.
• Manufacture sellable Petrifilm product and begin the multi-quarter manufacturing transition in November 2026.
• Achieve the first completed fully validated single kit unit (SKU) for Petrifilm by the end of August 2026.
• Implement the new global go-to-market strategy and solutions-based selling model.
• Continue cooperation with ACCC and NZCC regarding the genomics divestiture review.

Key Dates

Recommendation

The company shows signs of recovery with improved core growth and profitability metrics, and has a clear FY27 outlook. However, overall revenue is still declining, and the successful execution of the genomics divestiture and subsequent strategic initiatives are critical. A 'hold' recommendation reflects the balance between positive operational trends and ongoing strategic execution risks.

Keywords

Food Safety, Animal Safety, Genomics, Petrifilm, Listeria, New World Screwworm, FIFRA, AOAC